Overview

The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover

Status:
Completed
Trial end date:
2021-03-15
Target enrollment:
Participant gender:
Summary
The investigators believe that the emerging epidemiological evidence connecting topical use of corticosteroids to the development of type 2 diabetes and osteoporosis point to potentially massive, yet clinically unacknowledged problems associated with topical corticosteroid treatment. Using state-of-the-art methodology, the present study will delineate the impact of topical corticosteroid use on insulin sensitivity and bone turnover markers in patients with atopic dermatitis and, thus, provide important data that may have implications for millions of people using topical corticosteroids.
Phase:
Phase 4
Details
Lead Sponsor:
Jacob Thyssen
Collaborator:
LEO Pharma
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcineurin Inhibitors
Insulin
Tacrolimus